Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.
📚 期刊: Journal of the American College of Cardiology📅 发表: 0000-00-00🔬 PMID: 42126372👁️ 浏览: 49
Parikh, DeRubertis, Bonaca, Krishnan, Pin, Lee, Metzger, Kolluri, Shishehbor, Holden, Iida, Armstrong, Kum, O'Connor, Bajakian, Garcia, Ying, Wang, Ruster, Martinsen, Igyarto, Varcoe (0000). Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.. Journal of the American College of Cardiology
🔗 分享文献
📝 摘要
Chronic limb-threatening ischemia (CLTI) caused by infrapopliteal disease is a major therapeutic challenge, with percutaneous transluminal angioplasty (PTA) associated with high rates of restenosis and reintervention. The LIFE-BTK trial previously demonstrated superior efficacy of the Esprit (Abbott Vascular) BTK drug-eluting resorbable scaffold (DRS) over PTA at 1 year, with sustained benefits at 2 years, with comparable safety at both time points. This report presents the 3-year outcomes.